tweenvest

AgomAb Therapeutics NV (NasdaqGS: AGMB)

Salud · Farmacéuticas · BE

6,36 $

0,00 % hoy · -56,6 % 1 año

Ficha pública
Un resumen gratuito de AgomAb Therapeutics NV, con datos del 15 nov 2026. El análisis completo está en la app.Abrir en la app

AgomAb Therapeutics NV (NasdaqGS: AGMB) opera en la industria de farmacéuticas dentro del sector salud. Su valor en bolsa es de 313,22 M $ y tiene 62 empleados.

En los últimos doce meses la acción ha bajado un 56,6 % y ha cotizado entre 6,36 y 17,82.

Tweenvest puntúa a AgomAb Therapeutics NV en cuatro factores: calidad 50/100, valor 100/100. Su punto más fuerte es valor.

Evolución de la cotización de AGMB

6 feb 2026 · 14,65Cierres semanales 6,36 – 16,0213 nov 2026 · 6,36

Cifras clave

Capitalización
313,22 M $
Ingresos (últ. 12 m)
—
PER
-4,44
BPA
-168,16
Rent. por dividendo
—
Beta (5 años)
—
Máximo 52 semanas
17,82 $
Mínimo 52 semanas
6,36 $
Volumen medio (3 m)
—
Acciones en circulación
49,25 M
Empleados
62
Próximos resultados
—

Sobre AgomAb Therapeutics NV

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.

ISIN
US00860C1027
Fundada en
2017
Cotiza desde
6 feb 2026
Bolsa
Nasdaq Global Select
Divisa
USD
EmpresaCapitalizaciónPrecioDía
Swedencare AB (publ)OM: SECARE320,97 M $20,45 Skr+2,25 %
Zhejiang Shengda Bio-Pharm Co., Ltd.SHSE: 603079319,21 M $11,42 CN¥-1,72 %
Shandong Sito Bio-technology Co., Ltd.SZSE: 300583315,17 M $11,09 CN¥-1,68 %
Nile Pharmaceuticals and Chemical Industries CompanyCASE: NIPH313,45 M $335,00 EGP+3,07 %
Hainan Huluwa Pharmaceutical Group Co., Ltd.SHSE: 605199312,07 M $5,20 CN¥-2,80 %
Honz Pharmaceutical Co., Ltd.SZSE: 300086309,25 M $4,53 CN¥-3,00 %
Deva Holding A.S.IBSE: DEVA306,38 M $77,15 TL-1,47 %
Relmada Therapeutics, Inc.NasdaqCM: RLMD304,61 M $2,86 $-4,99 %

Ver todas las empresas de farmacéuticas →